Lexicon completes enrollment in Phase 3 HCM trial of sotagliflozin

July 27, 2026 8:30 AM

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced it has completed patient enrollment in its pivotal Phase 3 SONATA-HCM clinical trial, which is ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found